2021
Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study
Gutierrez JI, Dubov A, Altice FL, Vlahov D. Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study. Military Medical Research 2021, 8: 32. PMID: 34006328, PMCID: PMC8132436, DOI: 10.1186/s40779-021-00323-6.Peer-Reviewed Original ResearchConceptsDaily tabletHuman immunodeficiency virus (HIV) infectionMilitary healthcare settingsImmunodeficiency virus infectionPre-exposure prophylaxisU.S. military menTelehealth visitsResultsA totalVirus infectionProvider typeUtility scoresPrEP programHealthcare settingsMental healthMilitary providersProphylaxisMenSexInjectionConjoint analysis studyMilitary menService deliverySocial media groupsMedia groupsMedications
2013
Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia
Margolis B, Al-Darraji HA, Wickersham JA, Kamarulzaman A, Altice FL. Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 1538-1544. PMID: 24200265, PMCID: PMC3913085, DOI: 10.5588/ijtld.13.0193.Peer-Reviewed Original ResearchConceptsLatent tuberculous infectionTuberculin skin testTB symptomsTuberculous infectionTwo-step tuberculin skin testPrevious incarcerationHuman immunodeficiency virus (HIV) infectionLower body mass indexReactive tuberculin skin testImmunodeficiency virus infectionBody mass indexRoutine screening procedureCross-sectional surveyCD4 statusRoutine tuberculosisTST reactivityTuberculosis symptomsActive tuberculosisLTBI prevalenceOnly significant correlateMass indexNortheastern MalaysiaSkin testVirus infectionHIVImplementing methadone maintenance treatment in prisons in Malaysia
Wickersham JA, Marcus R, Kamarulzaman A, Zahari MM, Altice FL. Implementing methadone maintenance treatment in prisons in Malaysia. Bulletin Of The World Health Organization 2013, 91: 124-129. PMID: 23554524, PMCID: PMC3605007, DOI: 10.2471/blt.12.109132.Peer-Reviewed Original ResearchConceptsDose of methadoneMMT programHIV infectionHuman immunodeficiency virus (HIV) infectionMethadone maintenance treatment programDaily oral doseImmunodeficiency virus infectionMethadone maintenance treatmentMaintenance treatment programHarm reduction strategiesMinistry of HealthAdequate dosingOral doseMaintenance treatmentMethadone treatmentStandard operating proceduresMMT clientsVirus infectionTreatment programMethadoneOngoing educationInfectionDosePhase 3Tuberculosis
2011
Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components
Springer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Diseases 2011, 53: 469-479. PMID: 21844030, PMCID: PMC3156144, DOI: 10.1093/cid/cir446.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCombination antiretroviral therapyPublic health implicationsTreatment outcomesPoor HIV treatment outcomesHuman immunodeficiency virus (HIV) infectionImmunodeficiency syndrome prevalenceHIV treatment outcomesImmunodeficiency virus infectionHealth implicationsMental illness treatmentSubstance use disordersCase management servicesAntiretroviral therapySecondary preventionSyndrome prevalenceTransitional careImmunological outcomesCriminal justice populationsVirus infectionIllness treatmentUse disordersHIVMental illnessAlcohol useMedical insurance
2006
The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 2006, 43: s178-s183. PMID: 17109304, DOI: 10.1086/508181.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersRisk AssessmentSeverity of Illness IndexSubstance Abuse DetectionSubstance Abuse Treatment CentersSurvival AnalysisTreatment OutcomeUnited StatesConceptsHIV clinical care settingsHIV treatment outcomesClinical care settingsRole of buprenorphineOpioid dependenceTreatment outcomesCare settingsHuman immunodeficiency virus (HIV) infectionStudies of buprenorphineImmunodeficiency virus infectionHIV infection preventionUntreated opioid dependenceAntiretroviral therapyHIV carePreventive therapySecondary preventionAntiretroviral treatmentBuprenorphine treatmentHIV infectionOpportunistic infectionsSuccessful treatmentInfection preventionVirus infectionBuprenorphineInfected individuals
2003
Human Immunodeficiency Virus Infection with Human Granulocytic Ehrlichiosis Complicated by Symptomatic Lactic Acidosis
Springer SA, Altice FL. Human Immunodeficiency Virus Infection with Human Granulocytic Ehrlichiosis Complicated by Symptomatic Lactic Acidosis. Clinical Infectious Diseases 2003, 36: e162-e164. PMID: 12802782, DOI: 10.1086/374930.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisSymptomatic hyperlactatemiaLactic acidosisNormal serum lactate levelsHuman immunodeficiency virus (HIV) infectionNucleoside reverse transcriptase inhibitorSymptomatic lactic acidosisImmunodeficiency virus infectionSerum lactate levelsHuman immunodeficiency virusReverse transcriptase inhibitorAcute coinfectionAntiretroviral therapyHIV infectionHepatic insultImmunodeficiency virusAppropriate treatmentVirus infectionLactate levelsFirst presentationGranulocytic ehrlichiosisPatientsHyperlactatemiaAcidosisInfection
1999
Clinical Guidelines and Pharmacist Intervention Program for HIV‐Infected Patients Requiring Granulocyte Colony‐Stimulating Factor Therapy
Engles‐Horton L, Skowronski C, Mostashari F, Altice F. Clinical Guidelines and Pharmacist Intervention Program for HIV‐Infected Patients Requiring Granulocyte Colony‐Stimulating Factor Therapy. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 1999, 19: 356-362. PMID: 10221375, DOI: 10.1592/phco.19.4.356.30938.Peer-Reviewed Original ResearchConceptsIntervention periodPreintervention periodFactor therapyG-CSFGranulocyte colony-stimulating factor therapyHuman immunodeficiency virus (HIV) infectionColony-stimulating factor therapyPharmacist intervention programPharmacist-based interventionMean hospital stayImmunodeficiency virus infectionHospital medical information systemG-CSF dosesNumber of patientsMedical house staffTherapeutics subcommitteeHospital stayPharmacist interventionsChart reviewHospitalized patientsClinical pharmacistsImmunodeficiency syndromePatient morbidityPharmacy costsClinical guidelines
1996
Invasive Pneumococcal Disease: Clinical Features, Serotypes, and Antimicrobial Resistance Patterns in Cases Involving Patients with and Without Human Immunodeficiency Virus Infection
Frankel R, Virata M, Hardalo C, Altice F, Friedland G. Invasive Pneumococcal Disease: Clinical Features, Serotypes, and Antimicrobial Resistance Patterns in Cases Involving Patients with and Without Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1996, 23: 577-584. PMID: 8879783, DOI: 10.1093/clinids/23.3.577.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal diseaseClinical featuresPenicillin-resistant pneumococcal infectionsHuman immunodeficiency virus (HIV) diseaseHuman immunodeficiency virus (HIV) infectionCommon capsular typesSource of bacteremiaImmunodeficiency virus infectionOverall mortality rateAntibiotic susceptibility patternPolyvalent pneumococcal vaccineType 9VCommon risk factorsPenicillin-resistant isolatesAntimicrobial resistance patternsPneumococcal infectionPneumococcal vaccineHIV infectionHIV serostatusHIV statusRecurrence rateInvasive diseaseRisk factorsSusceptibility patterns